Also known as flu jabs or flu shots, influenza vaccines are defined as vaccines that protect against infection by influenza viruses. According to a report from World Health Organization (WHO), the world witnesses around 3 to 5 million cases of influenza-based diseases annually. Hence, the proactive measures to contain this are implemented by different governments in full swing. According to study, 69,009 people in North America were diagnosed with the influenza virus in 2018. Among these, 67,733 people were diagnosed with influenza A virus and the rest of them were diagnosed with influenza B virus. In 2010, the cases of influenza infection in USA increased from 9.2 million cases to 49.0 million cases. US Food & Drug Administration (FDA) approved the Xofluza from Roche which can prevent influenza after contact with an infected person. Indian Institute of Science (IISc)-incubated Mynvax is also working to develop novel recombinant vaccines for COVID-19 and human influenza. Their plan is to use the proceeds in further clinical developments too.
The major factor driving the global influenza vaccine market is the growing prevalence of influenza across the world. Increasing cases of influenza is accelerating the growth of global influenza vaccine market. As influenza viruses undergo constant genetic change, these changes many times give them immunity against vaccines and thus, very often, medicines meant to cure influenza do not affect the genetically mutated viruses. Hence, rising demand along with investment in the production of new influenza vaccines, is estimated to contribute towards the growth of global influenza vaccine market over the forecast period. With the expansion in influenza epidemics, the research to develop new vaccines has also increased, inviting incentives and support from government, along with the investment for the same.
Request for Sample Copy of This Report@
https://www.absolutemarketsinsights.com/request_sample.php?id=873
Increasing government spending towards availability and distribution of flu vaccines showcases substantial growth opportunity for the global influenza vaccine market over the period of next eight years. Many governments around the world are carrying out extensive vaccination drives before the flu season begins to immunize people from contracting influenza infections, which is stimulating the growth of seasonal influenza vaccine market. WHO and the United Nations’ Children Fund (UNICEF) regularly recommend various seasonal influenza vaccines and general influenza vaccines to regional public authorities. These factors are expected to ensure a robust growth for global influenza vaccine market. WHO-supported Global Influenza Surveillance and Response System (GISRS) is also facilitating research through increased funding for the development of up-to-date vaccines. This has enabled governments around the world to launch broad-based domestic immunization drives. Hence, the development of such vaccines is expected to play a central role in determining trends in the global influenza vaccine market during the forecast period. According to different studies conducted recently, people vaccinated for influenza did show resistance to some of the symptoms of COVID-19. Hence, using influenza vaccines for experiments in efforts to develop vaccine to prevent coronavirus showcases new opportunity in the global influenza vaccine market.
Enquiry Before Buying@
https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=873
Key Findings of the Report:
- The global influenza vaccine market is anticipated to reach US $ 7824.08 Mn by 2029 growing at a CAGR of 6.6% during the forecast period (2021 – 2029)
- The quadrivalent flu vaccines category, which dominated the global influenza vaccine market, can save the receiver from four strains of influenza. In influenza A, quadrivalent flu vaccines fight against the H1N1 (swine flu) and H3N2. In influenza B, this vaccine fights against two strains namely Victoria and Yamagata. The quadrivalent flu vaccines are also suitable for not only most age-groups above 18 years of age, but also for children aged 6 or above.
- The seasonal category in the global influenza vaccine market held the larger market share in 2020. Influenza viruses change from year to year. Hence, influenza vaccines need to be updated annually to include the viruses that will most likely circulate in the upcoming season. In countries where frequent seasonal changes are common, there is high demand for universal influenza vaccines that offer protection against multiple strains of influenza viruses over multiple influenza seasons.
- In 2020, intramuscular injection segment occupied the largest market. It has been the most common form of dosage for influenza prevention for decades. As an inactivated vaccine, the Flu vaccine contains killed influenza virus. As a recombinant vaccine, it is made without using virus particles at all. When healthcare providers inject the vaccine into muscles or skin, they stimulate the immune system to produce an immune response (in the form of antibodies) to the influenza virus.
- In 2020, North America was the biggest regional market in the global influenza vaccine market. Proper utilization of advanced manufacturing systems and processes for vaccines along with advanced medical sector in countries like USA and Canada have contributed towards the increased share of the region in the global market. Other factors contributing to the market growth in this region include availability of advanced medical devices useful for the production of medicines as well as vaccines, rising incidence of influenza, presence of major market players, well-funded vaccine research programs, and government support for such programs along with many incentives.
- Some of the major players operating in the global influenza vaccine market are Abbott, AstraZeneca, CSL Limited (Seqirus USA Inc.), Emergent BioSolutions Inc., F. Hoffmann-La Roche Ltd, GSK, Novavax Inc., SANOFI PASTEUR INC., Serum Institute of India Pvt. Ltd., and Sinovac Biotech Ltd. amongst others.
Request for Customization@
https://www.absolutemarketsinsights.com/request_for_customization.php?id=873
Global Influenza Vaccine Market:
- By Vaccine Type
- Trivalent Flu Vaccines
- Quadrivalent Flu Vaccines
- By Influenza Type
- Seasonal
- Pandemic
- Others
- By Type
- Live Attenuated Influenza Vaccine (LAIV)
- Inactivated Influenza Vaccine (IIV)
- Recombinant Influenza Vaccine (RIV)
- By Manufacturing Technology
- Egg Based
- Cell Based
- By Packaging
- Prefilled Needleless Syringes
- Single Dose and Multi-Dose Vial
- By Dosage Form
- Intramuscular Injection
- Intradermal Shot
- Nasal Spray
- By Age Group
- 6 months to 4 Years
- 4 Years to 18 Years
- 18 Years to 49 Years
- 49 Years to 65 Years
- More than 65 Years
- By Distribution Channel
- Doctors’ Offices
- Healthcare Clinics
- Retail Pharmacies
- Hospitals
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Get More Information@ https://www.absolutemarketsinsights.com/reports/Influenza-Vaccine-2021---2029-873
About Us:
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization. From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.
Contact Us:
Company: Absolute Markets Insights
Contact Name: Shreyas Tanna
Phone: +91-740-024-2424
Email id: [email protected]
Website: https://www.absolutemarketsinsights.com